

Revision date: 06-Feb-2012 Version: 2.0 Page 1 of 8

## IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc **Pfizer Pharmaceuticals Group** 235 East 42nd Street New York, New York 10017 1-212-573-2222

**Emergency telephone number:** CHEMTREC (24 hours): 1-800-424-9300 **Contact E-Mail:** pfizer-MSDS@pfizer.com Pfizer Ltd Ramsgate Road Sandwich, Kent **CT13 9NJ United Kingdom** +00 44 (0)1304 616161

**Emergency telephone number:** 

International CHEMTREC (24 hours): +1-703-527-3887

Material Name: Meloxicam Tablets

**Trade Name:** Not established

**Chemical Family:** Mixture

Intended Use: Pharmaceutical product used as non-steroidal, anti-inflammatory drug (nsaid)

## 2. HAZARDS IDENTIFICATION

Appearance: **Tablets** Signal Word: **DANGER** 

Statement of Hazard: Harmful if swallowed.

May damage the unborn child.

**Additional Hazard Information:** 

**Short Term:** Accidental ingestion may cause effects similar to those seen in clinical use.

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on heart and

gastrointestinal system.

Ingestion of this material may cause effects similar to those seen in clinical use including **Known Clinical Effects:** 

> serious gastrointestinal toxicity such as bleeding, ulceration, and perforation and kidney toxicity. Occasional, transient changes reported in liver function tests, but no liver damage seen. Other nonsteroidal anti-inflammatory drugs (NSAIDs) are known to impact delivery, late fetal development, and lactation. Hypersensitivity reactions may also occur in susceptible

individuals.

**EU Classification** 

EU Indication of danger: Harmful

Toxic to reproduction: Category 1

**EU Hazard Symbols:** 



**EU Risk Phrases: EU Risk Phrases:** 

R22 - Harmful if swallowed.

R61 - May cause harm to the unborn child. Hazardous Substance. Non-Dangerous Goods.

**Australian Hazard Classification** 

(NOHSC):

PZ01219

**Material Name: Meloxicam Tablets** Page 2 of 8 Revision date: 06-Feb-2012 Version: 2.0

## 2. HAZARDS IDENTIFICATION

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

# 3. COMPOSITION/INFORMATION ON INGREDIENTS

#### Hazardous

Tidadi dodo						
Ingredient	CAS Number	<b>EU EINECS/ELINCS List</b>	<b>EU Classification</b>	%		
Meloxicam	71125-38-7	Not Listed	T;R25	7.5 or 15 mg***		
			Repr.Cat.1;R61			
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	*		
Silica colloidal, Ph. Eur.	112945-52-5	Not Listed	Not Listed	*		
Magnesium stearate	557-04-0	209-150-3	Not Listed	*		

Ingredient	CAS Number	<b>EU EINECS/ELINCS List</b>	<b>EU Classification</b>	%
Lactose NF, anhydrous	63-42-3	200-559-2	Not Listed	*
Sodium citrate	68-04-2	200-675-3	Not Listed	*
Crospovidone	9003-39-8	Not Listed	Not Listed	*
Povidone	9003-39-8	Not Listed	Not Listed	*
Lactose NF, monohydrate	64044-51-5	Not Listed	Not Listed	*

**Additional Information:** \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

For the full text of the R phrases mentioned in this Section, see Section 16

## 4. FIRST AID MEASURES

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention **Eye Contact:** 

immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

# 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

Material Name: Meloxicam Tablets Page 3 of 8
Revision date: 06-Feb-2012 Version: 2.0

Hazardous Combustion Products: Carbon monoxide, carbon dioxide, oxides of nitrogen, oxides of sulfur, hydrochloride, and other

chlorine-containing compounds

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

## 6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

**Measures for Environmental** 

**Protections:** 

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

**Additional Consideration for Large** 

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

**General Handling:** Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken,

avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or

other equivalent controls.

**Storage Conditions:** Store as directed by product packaging.

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
Estonia OEL - TWA 10 mg/m³
France OEL - TWA 10 mg/m³
Ireland OEL - TWAs 10 mg/m³
4 mg/m³

Latvia OEL - TWA 2 mg/m³

OSHA - Final PELS - TWAs: 15 mg/m³

Portugal OEL - TWA 10 mg/m³

Romania OEL - TWA 10 mg/m³

Spain OEL - TWA 10 mg/m³

Silica colloidal, Ph. Eur.

Austria OEL - MAKs 4 mg/m<sup>3</sup>

Material Name: Meloxicam Tablets Page 4 of 8
Revision date: 06-Feb-2012 Version: 2.0

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Magnesium stearate

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Lithuania OEL - TWA 5 mg/m³
Sweden OEL - TWAs 5 mg/m³

Meloxicam

Pfizer Occupational Exposure OEB 4 (control exposure to the range of >1ug/m³ to <10ug/m³)

Band (OEB):

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental

legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

Respiratory protection: If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear

an appropriate respirator with a protection factor sufficient to control exposures to the bottom of

the OEB range.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Tablets Color: No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

## 10. STABILITY AND REACTIVITY

**Chemical Stability:** Stable under normal conditions of use.

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

## 11. TOXICOLOGICAL INFORMATION

**General Information:** The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

**Povidone** 

Rat Oral LD50 100 g/kg

Material Name: Meloxicam Tablets Page 5 of 8
Revision date: 06-Feb-2012 Version: 2.0

## 11. TOXICOLOGICAL INFORMATION

#### Meloxicam

Rat Oral LD50 83.5 mg/kg Mouse Oral LD50 470 mg/kg Rabbit Oral LD50 320 mg/kg

#### Magnesium stearate

Rat Oral LD50 > 2000 mg/kg Rat Inhalation LC50 > 2000 mg/m<sup>3</sup>

#### Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg Rabbit Dermal LD50 > 2000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

#### Meloxicam

Skin Sensitization - M & K Guinea Pig Negative

### Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating Eye Irritation Rabbit Non-irritating

### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

### Meloxicam

52 Week(s) Rat Oral 0.2 mg/kg b.w. NOEL Kidney, Gastrointestinal System 4 Week(s) Dog Oral 0.4 mg/kg b.w. NOEL Gastrointestinal system, Kidney

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

### Meloxicam

Embryo / Fetal Development Rat Oral 1 mg/kg/day LOAEL Not teratogenic, Embryotoxicity, Maternal toxicity Fertility and Embryonic Development Rat Oral 0.125 mg/kg/day LOAEL Neonatal mortality, Neonatal toxicity Embryo / Fetal Development Rabbit Oral 1 mg/kg/day LOAEL Embryotoxicity, Not Teratogenic

### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

#### Meloxicam

Bacterial Mutagenicity (Ames) Salmonella Negative In Vivo Micronucleus Mouse Bone Marrow Negative

## Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### Meloxicam

104 Week(s) Rat Oral 0.8 mg/kg/day NOEL Not carcinogenic 2 Year(s) Mouse Oral 8 mg/kg/day NOAEL Not carcinogenic

### Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

#### Crospovidone

P704040

PZ01219

Material Name: Meloxicam Tablets Page 6 of 8
Revision date: 06-Feb-2012 Version: 2.0

## 11. TOXICOLOGICAL INFORMATION

IARC: Group 3 (Not Classifiable)

**Povidone** 

IARC: Group 3 (Not Classifiable)

Silica colloidal, Ph. Eur.

IARC: Group 3 (Not Classifiable)

## 12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

## 13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## 15. REGULATORY INFORMATION

EU Indication of danger: Harmful

Toxic to reproduction: Category 1

EU Risk Phrases: EU Risk Phrases:

R22 - Harmful if swallowed.

R61 - May cause harm to the unborn child.

**EU Safety Phrases:** 

S22 - Do not breathe dust.

S53 - Avoid exposure - obtain special instructions before use.

**OSHA Label:** 

DANGER

Material Name: Meloxicam Tablets Page 7 of 8
Revision date: 06-Feb-2012 Version: 2.0

## 15. REGULATORY INFORMATION

Harmful if swallowed.

May damage the unborn child.

#### Canada - WHMIS: Classifications

### WHMIS hazard class:

Class D, Division 2, Subdivision B Class D. Division 1, Subdivision B



Meloxicam

Standard for the Uniform Scheduling Schedule 4 for Drugs and Poisons:

Lactose NF, anhydrous

Inventory - United States TSCA - Sect. 8(b)PresentAustralia (AICS):PresentREACH - Annex IV - Exemptions from thePresent

obligations of Register:

EU EINECS/ELINCS List 200-559-2

Microcrystalline cellulose

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

232-674-9

Sodium citrate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
200-675-3

Crospovidone

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present

**Povidone** 

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present

Silica colloidal, Ph. Eur.

Australia (AICS): Present

Lactose NF, monohydrate

Australia (AICS): Present

Magnesium stearate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
209-150-3

Material Name: Meloxicam Tablets Page 8 of 8
Revision date: 06-Feb-2012 Version: 2.0

Version date. 00-1 eb-2012

# 15. REGULATORY INFORMATION

## **16. OTHER INFORMATION**

## Text of R phrases mentioned in Section 3

R25 - Toxic if swallowed.

R61 - May cause harm to the unborn child.

**Data Sources:** Publicly available toxicity information. Safety data sheets for individual ingredients.

**Reasons for Revision:** Updated Section 8 - Exposure Controls / Personal Protection.

Prepared by: Product Stewardship Hazard Communication

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**